Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Finerenone (Primary)
  • Indications Cardiovascular disorders; Diabetic nephropathies; Renal failure
  • Focus Registrational; Therapeutic Use
  • Acronyms FIDELIO-DKD
  • Sponsors Bayer

Most Recent Events

  • 25 Mar 2025 According to Bayer media release, data from this trial will be presented at the American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025
  • 22 Feb 2024 Results assessing dose-exposure-response analyses to determine the effects of finerenone doses in FIGARO-DKD and FIDELIO-DKD trials, published in the Diabetes, Obesity and Metabolism.
  • 01 Jan 2024 Results of pooled, subgroup analysis from FIDELIO-DKD and FIGARO-DKD; investigating the effect of finerenone on liver function, cardiovascular and kidney composite outcomes in patients with chronic kidney disease and type 2 diabetes, stratified by their risk of liver steatosis, inflammation and fibrosis, published in the Diabetes, Obesity and Metabolism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top